Clincosm LogoSign in Get a demo

REACT: Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire

Sponsor
Institut de Recherche pour le Developpement (Other)
Overall Status
Unknown status
CT.gov ID
NCT03074435
Collaborator
Institut de Recherche en Sciences de la Sante, Burkina Faso (Other), Institut Pierre Richet (Other)
18,000
Enrollment
5
Arms
36
Duration (Months)

Study Details

Study Description

Brief Summary

This study evaluates the benefit to use 1) insecticidal paints, 2) larvicides, 3) Ivermectin for both human and domestic animals and 4) strengthened Information, Education and Communication (IEC) strategy to complement the universal coverage with LLINs through a cluster randomized trial.

Condition or Disease Intervention/Treatment Phase
  • Device: Insecticidal paint
  • Device: Larvicide
  • Biological: Ivermectin
  • Behavioral: IEC
 Phase 3

Detailed Description

Insecticidal paint comprised of two organophosphates (OPs) and an Insect Growth Regulator (IGR). This tool targets adult mosquitoes that are resistant pyrethroids to reduce vector density.

Larvicide is a new formulation of Bacillus thuringiensis israelensis that will be implemented in major permanent breeding sites with the objective to reduce vector density.

Ivermectin will be injected to domestic animals in addition to the national campaign implemented in the study area which treats the whole population. Ivermectin reduces the survival of mosquito that blood feed on treated humans and animals.

Information, Education and Communication strategy aims to increase the adherence of the population to control tools available. Strengthening the IEC aims to increase the good use of long lasting nets.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
18000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire: Research on Vector Control Strategies
Study Start Date :
Apr 1, 2016
Anticipated Primary Completion Date :
Oct 1, 2017
Anticipated Study Completion Date :
Apr 1, 2019

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

No intervention
Experimental: insecticidal paint

The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.

Device: Insecticidal paint
Houses will be painted with insecticidal paint
Other Names:
  • Inestfly 5A IGR

    		•
    Experimental: Larvicides

    The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.

    Device: Larvicide
    Larval breeding sites will be treated with larvicide
    Experimental: Ivermectin

    This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.

    Biological: Ivermectin
    Doses of Ivermectin will be injected to peri-domestic animals
    Experimental: Information, Education, Communication

    After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one

    Behavioral: IEC
    A reinforced information, education and communication strategy will be implemented.

    Outcome Measures

    Primary Outcome Measures

    1. Malaria incidence [continuous monitoring during 2 years]

      Malaria cases reported in local health system

    Secondary Outcome Measures

    1. Entomological Inoculation Rate [Every 8 weeks during 2 years]

      Number of infectious bites/personn

    2. Malaria prevalence [Every 4 months during 2 years]

      % of positive blood smears among the population between 6 months to 20 years

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    6 Months to 20 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Must be an inhabitant of the villages included into the RCT

    • Aged from 6month old to 20 years old

    Exclusion Criteria:
    • older than 20 year old

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Institut de Recherche pour le Developpement
    • Institut de Recherche en Sciences de la Sante, Burkina Faso
    • Institut Pierre Richet

    Investigators

    • Principal Investigator: Cédric Pennetier, PhD, Institut de Rehcerche pour le Développement

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Cédric PENNETIER, Principal Investigator, Institut de Recherche pour le Developpement
    ClinicalTrials.gov Identifier:
    NCT03074435
    Other Study ID Numbers:
    • InstitutRD
    First Posted:
    Mar 8, 2017
    Last Update Posted:
    Mar 10, 2017
    Last Verified:
    Mar 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:
    Malaria
    Ivermectin

    Study Results

    No Results Posted as of Mar 10, 2017